Taskforce notes concerns about potential Ronapreve effectiveness and Omicron
23 December, 2021
The Taskforce has added the following statement to the remark in all for use casirivimab plus imdevimab recommendations. The Taskforce is aware of concerns about the potential for decreased effectiveness of casirivimab plus imdevimab against the Omicron variant, based on in vitro data. We will update this recommendation as definitive evidence becomes available. Ends.